Clinical Trials ArenaOriginal article
Rocket points to Danon gene therapy’s safety after Phase II protocol change
Phase 2positiveRP-A501Positive
AI Analysis
Summary
Rocket Pharmaceuticals reported that three patients with Danon disease safely received its gene therapy RP-A501, with no observed cases of capillary leak syndrome following a Phase 2 protocol change.
Clinical Trial Data
Phase
Phase 2
Patients
3
Outcome Details
Three patients safely received RP-A501 with no cases of capillary leak syndrome observed
Importance:5/10
Sentiment:
0.70
gene therapysafety dataDanon diseaseprotocol changecapillary leak syndrome
Related Companies
Read the original article
Published by Clinical Trials Arena on August 4, 2026 10:03 AM